This online, on-demand virtual symposium brings together renowned ophthalmologists and optometrists to discuss managing ocular toxicities associated with select antibody-drug conjugates, monoclonal antibodies, and selective estrogen receptor degraders to optimize patient outcomes and to improve collaborative, multidisciplinary care, including shared...

Recent advances in the treatment of presbyopia have focused on pharmacological agents as a novel therapeutic strategy that offers noninvasive, reversible options capable of enhancing depth of focus without altering the natural lens structure. As new and emerging pharmacological therapies...

Modern glaucoma management incorporates a wide variety of therapies, with more options becoming available recently. This educational program offers expert perspectives on individualizing glaucoma therapy with topical medications, selective laser trabeculoplasty, sustained-release drug implants, and micro-invasive glaucoma surgery procedures, providing...

Macular telangiectasia type 2 (MacTel) is a rare, progressive retinal disease characterized by neurodegenerative changes, localized retinal degeneration, and alterations in the retinal vasculature. It usually presents bilaterally and leads to gradual central vision loss, and its early signs and...

Patients with diabetic retinopathy (DR) or diabetic macular edema (DME) tend to have a host of comorbidities and a considerable burden of required treatments and medical appointments. Recent additions to treatment options for DR and DME provide opportunities to reduce...